Skip to main content

Dake Benjamin T's Form 4 filing

Jade Biosciences, Inc. (JBIO) · filed Oct 18, 2022

Accession no.
0001415889-22-010651
Filed
Oct 18, 2022
Trade date
Oct 14-17, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $86.6K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dake Benjamin TCIK 0001869248Officer (SEE REMARKS)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 14, 2022Common StockMOption exerciseAcquired+110$2.14+$235.4110Direct
Oct 14, 2022Common StockSSaleDisposed−110$20.05−$2,205.50Direct
Oct 17, 2022Common StockMOption exerciseAcquired+4,185$2.14+$8,955.94,185Direct
Oct 17, 2022Common StockSSaleDisposed−4,185$20.16F2−$84,369.60Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 14, 2022Common StockMOption exerciseDisposed−110$0.00$0309,056Direct
Oct 17, 2022Common StockMOption exerciseDisposed−4,185$0.00$0304,871Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.602, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Remarks

Officer Title: President, Chief Operating Officer and Secretary

Read the full filing on SEC EDGAR (opens in a new tab)